



Aurélien Marabelle

MD
PhD

General background

Aurélien Marabelle MD, PhD, is a Senior Medical Oncologist in the Drug Development Department (DITEP), a group leader in Prof Laurence Zitvogel's lab (INSERM U1015) and the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy. He joined the faculty in Oct 2014.

He got a MSc & PhD in Oncology & Immunology from Ecole Normale Supérieure de Lyon, King's College London & University of Lyon. He did a post-doctoral fellowship in Prof Ronald Levy's lab at Stanford University, California.

He trained at the University of Paris VI medical school and received his medical degree from the University of Clermont-Ferrand. He completed his residency training in between Clermont-Ferrand & Lyon, followed by a clinical fellowship at Léon Bérard Cancer Center in Lyon.

Dr Marabelle is a member of ASCO & AACR. Dr Marabelle is board-certified in Pediatric Oncology & Cell Therapy.

Research axes: Cancer Immunotherapy & Early Phase Studies

IMMUNOTHERAPY & EARLY CLINICAL TRIALS EXPERTISE

ORAL PRESENTATIONS

SITC 2017

- Phase I study of E7046, a novel PGE2-receptor type-4 inhibitor, in patients with advanced solid tumors: clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression

ASCO GI 2016

- Understanding the relevant immune mechanisms in GI cancer

ITOC3 2016

- Prioritisation of potential immunotherapy combination studies

TAT 2015

- "Novel Immunostimulatory Antibodies: What's next?"

PUBLICATIONS

- Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, **Marabelle A**, Soria JC, Ferte C. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. **Clin Cancer Res** 2017 Apr 15;23(8):1920-1928.
- **Marabelle A**, Aspeslagh S, Postel-Vinay S, Soria JC. JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. **Cancer Discov**. 2017;7(2):128-130.
- Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, **Marabelle A**. Rationale for anti-OX40 cancer immunotherapy. **Eur J Cancer**. 2016;52:50-66.
- Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, **Marabelle A**, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciu C, Eggermont AM, Soria JC, Mateus C, Robert C. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. **Nature reviews Clinical oncology**. 2016;13(8):473-486.
- Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, **Marabelle A**. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. **Ann Oncol**. 2016;27(2):214-224.
- Jacquilot N, Roberti MP, Enot DP, Rusakiewicz S, Ternes N, Jegou S, Woods DM, Sodre AL, Hansen M, Meirou Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dreno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, **Marabelle A**, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. **Nat Commun**. 2017 Sep 19;8(1):592.
- Shekarian T, Valsesia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, **Marabelle A**. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. **Ann Oncol**. 2017 Aug 1;28(8):1756-1766.